DUO-E : A Randomised, Multicentre, Double-blind, Placebo-controlled, Phase III Study of First-line Carboplatin and Paclitaxel in Combination With Durvalumab, Followed by Maintenance Durvalumab With or Without Olaparib in Patients With Newly Diagnosed Advanced or Recurrent Endometrial Cancer (DUO-E)

Female<br/>OnlyGender Female
Only

RecruitingStatus Recruiting

Systemic<br/>Therapy TrialTypeSystemic
Therapy Trial

ThreePhase Three

18-150Age 18-150

Female Reproductive<br/>System CancersCancer LocationFemale Reproductive
System Cancers

Systemic therapy,Treatment | Female reproductive organsEndometrium,Epithelial

Trial Overview Read MoreRead more

This phase III trial will assess the safety and effectiveness of a targeted cancer drug, given in combination with chemotherapy and followed by maintenance therapy, in patients with advanced or recurrent endometrial cancer.
 

This trial is treating patients with endometrial cancer.

This is a systemic therapy trial.

You may be excluded from this trial if:

  • You have a certain disease or psychological condition.
  • You have had certain treatments, surgical procedures or drugs.

Clinical trials have complex eligibility criteria - talk to your doctor about your interest in this trial.

Clinical Summary Read MoreRead more

Trial Identifiers

Use the hyperlinks, where available to access additional clinical trial information.

Scientific Title

A Randomised, Multicentre, Double-blind, Placebo-controlled, Phase III Study of First-line Carboplatin and Paclitaxel in Combination With Durvalumab, Followed by Maintenance Durvalumab With or Without Olaparib in Patients With Newly Diagnosed Advanced or Recurrent Endometrial Cancer (DUO-E)

Commercial Sponsor

AstraZeneca

Summary

Eligible patients will be randomised into one of three Arms of the trial (Arm A, B or C). Depending on their allocation, patients will receive Platinum-based chemotherapy and durvalumab placebo followed by maintenance therapy, containing durvalumab placebo and olaparib placebo (tablets), durvalumab and olaparib placebo or durvalumab and olaparib. : Platinum-based chemotherapy and durvalumab placebo followed by maintenance durvalumab placebo and olaparib placebo (tablets). Drug: durvalumab placebo : Olaparib tablets This Phase III study will assess the efficacy and safety of durvalumab in combination with platinum-based chemotherapy (paclitaxel + carboplatin) followed by maintenance durvalumab with or without olaparib for patients with newly diagnosed advanced or recurrent endometrial cancer.Target patient population: Adult female patients with histologically confirmed diagnosis of epithelial endometrial carcinoma (excluding sarcomas): newly diagnosed Stage III, newly diagnosed Stage IV, or recurrent endometrial cancer

Recruiting Hospitals Read MoreRead more

Cabrini Hospital
Malvern
Ms Mary Lane
mlane@cabrini.com.au
(03) 9508 1772

Monash Health, Medical Oncology
Clayton
Breast and Gynaecology Research Study Coordinator
breastgynae.oncresearch@monashhealth.org
0491299561

Trial Overview: General information about a clinical trial. This section provides an overview of who might be able to join this trial and what type of treatment is involved.

Next